Keith W. Pratz, MD on Phase 3 VIALE-A Study in AML @PennMedicine

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients.

https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo